Gc Biopharma Concludes Agreement With Acuitas Therapeutics For Lipid Nanoparticle Delivery System For Use In Mrna Vaccines And Therapeutics
Gc Biopharma And Acuitas Therapeutics, A Company Focused On Developing Lipid Nanoparticle (Lnp) Delivery Systems To Enable Messenger Rna (Mrna)-Based Therapeutics, Today Announced That They Have Entered Into A Development And Option Agreement For Acuitas